STOCK TITAN
  1. Home
  2. Sec-filings
  3. KAPA
  4. [EFFECT] Kairos Pharma, LTD. SEC Filing

[EFFECT] Kairos Pharma, LTD. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 23, 2026 9:00 A.M.
Form: S-3
CIK: 0001962011
Company Name: Kairos Pharma, LTD.
File Number: 333-292686

Source: View Original Filing on SEC EDGAR

Stock KAPA logo
KAIROS PHARMA LTD

NYSE:KAPA

KAPA Rankings

#6155 Ranked by Market Cap
N/A Ranked by Dividends
#87 Top Gainer

KAPA Latest News

Jan 20, 2026
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Dec 17, 2025
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Nov 4, 2025
Kairos Pharma Provides Shareholder Update
Oct 20, 2025
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
Oct 7, 2025
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

KAPA Latest SEC Filings

Jan 12, 2026
[S-3] Kairos Pharma, LTD. Shelf Registration Statement
Dec 30, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity
Dec 23, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity
Nov 26, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity
Nov 26, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity

KAPA Stock Data

15.87M
12.11M
38.38%
5.37%
2.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ANGELES